SCHEMBL18072475

SCHEMBL18072475

Cn1cc(-n2ccc3c(Oc4cc(C#N)cc(C(F)(F)F)n4)cccc32)cn1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 5/20 0.55
▸ KDM4E B2RXH2 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ SCN9A Q15858 4/20 0.33
▸ IRAK4 Q9NWZ3 2/20 0.32
▸ AXL P30530 1/20 0.32
▸ MERTK Q12866 1/20 0.32
▸ MAP4K1 Q92918 1/20 0.32
▸ SYK P43405 1/20 0.31
▸ SLC6A2 P23975 1/20 0.31
▸ SLC6A4 P31645 1/20 0.31
▸ SLC6A3 Q01959 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ ATM Q13315 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ GRM2 Q14416 1/20 0.31
▸ RHEB Q15382 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19755757 0.87 LOXL2 (0.40) LOXL2SCN9AIRAK4MAP4K1SYK
SCHEMBL28567884 0.85 LOXL2 (0.39) LOXL2KDM4EIRAK4AXLMERTK
Hydrochloric Acid SCHEMBL28574601 0.84 LOXL2 (0.39) LOXL2KDM4EAXLMERTKMAP4K1
SCHEMBL18049928 0.84 LOXL2 (0.55) LOXL2
SCHEMBL19739420 0.83 LOXL2 (0.37) LOXL2IRAK4AXLMERTKMAP4K1
Hydrochloric Acid SCHEMBL18050037 0.83 LOXL2 (0.55) LOXL2
SCHEMBL18361992 0.77 LOXL2 (0.38) LOXL2SCN9AIRAK4MAP4K1SYK
SCHEMBL19755754 0.72 LOXL2 (0.41) LOXL2IRAK4MAP4K1SYKGRM2
SCHEMBL18050107 0.72 LOXL2 (0.71) LOXL2KDM4ELMNAALDH1A1NPSR1
SCHEMBL28906716 0.71 LOXL2 (0.35) LOXL2MAP4K1SYKRHEB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2021-07-27 — — US disclosed
EP-3795568-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF Pharmakea, Inc. (US) 2021-03-24 — — EP disclosed
EP-3265456-B1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2020-11-18 — — EP disclosed
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2020-04-16 — — US disclosed
US-10570094-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2020-02-25 — — US disclosed
US-20190119211-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2019-04-25 — — US disclosed
WO-2016144703-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2016-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119211-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX LOXL2 1/4885KDM4E 1656/4885LMNA 175/4885
US-10570094-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX LOXL2 1/4885KDM4E 1656/4885LMNA 175/4885
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX LOXL2 1/4885KDM4E 1656/4885LMNA 175/4885
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX LOXL2 1/4885KDM4E 1656/4885LMNA 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback